PROFARMA GLOBAL - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 220,789 | 206,996 | 323,319 | 120,589 | 104,586 | 104,460 | 199,520 | 240,982 |
| Profit before tax | -39,331 | -47,846 | 49,866 | -70,139 | -115,352 | -45,796 | 57,722 | -1,935 |
| Net profit | -39,331 | -47,846 | 49,866 | -70,139 | -115,352 | -45,796 | 57,722 | -1,935 |
| Equity | -225,908 | -272,327 | -223,373 | -301,983 | -417,335 | -463,131 | -384,618 | -390,332 |
| Liabilities | 469,864 | 612,054 | 592,915 | 625,035 | 1,006,902 | 1,010,996 | 887,889 | 917,546 |
| Non-current assets | 6 | 6 | 1,120 | 721 | 322 | 403 | 220 | 37 |
| Current assets | 243,950 | 339,721 | 368,422 | 322,331 | 589,245 | 547,462 | 503,051 | 527,177 |
| Total assets | 243,956 | 339,727 | 369,542 | 323,052 | 589,567 | 547,865 | 503,271 | 527,214 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 18,872 | 57,031 | 48,033 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +34.2% | -6.2% | +56.2% | -62.7% | -13.3% | -0.1% | +91.0% | +20.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -16.1% | -14.1% | 13.5% | -21.7% | -19.6% | -8.4% | 11.5% | -0.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -17.8% | -23.1% | 15.4% | -58.2% | -110.3% | -43.8% | 28.9% | -0.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -17.8% | -23.1% | 15.4% | -58.2% | -110.3% | -43.8% | 28.9% | -0.8% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 29,769 | 39,428 | 73,204 | 29,532 | 34,862 | 35,814 | 66,507 | 80,327 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
PROFARMA GLOBAL - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-07-16 | 2025-07-20 | 11.05 |
| 2025-06-17 | 2025-07-07 | 11.12 |
| 2025-04-16 | 2025-04-16 | 434.46 |
| 2024-11-18 | 2024-11-20 | 2.15 |
| 2024-10-29 | 2024-11-06 | 3.10 |
| 2024-10-28 | 2024-10-28 | 3.03 |
| 2024-09-17 | 2024-10-09 | 0.92 |
| 2024-08-19 | 2024-09-05 | 1.20 |
| 2024-07-24 | 2024-08-07 | 1.36 |
| 2024-07-16 | 2024-07-17 | 5.49 |
| 2024-06-25 | 2024-07-11 | 105.78 |
| 2024-06-18 | 2024-06-24 | 365.78 |
| 2023-05-16 | 2023-05-17 | 42.35 |
| 2023-05-02 | 2023-05-10 | 44.23 |
| 2023-04-25 | 2023-04-28 | 44.23 |
| 2023-04-20 | 2023-04-24 | 44.09 |
| 2023-04-18 | 2023-04-19 | 482.09 |
| 2023-03-16 | 2023-03-26 | 39.08 |
| 2022-09-16 | 2022-09-19 | 10.50 |
| 2022-03-16 | 2022-04-10 | 0.54 |
| 2021-11-09 | 2021-11-14 | 0.06 |
| 2021-10-18 | 2021-10-19 | 179.56 |
PROFARMA GLOBAL - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-04-30 | 2026-05-07 | 10.66 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
PROFARMA GLOBAL, UAB (code 303519409) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of EUR 241.0K, up 20.8% year on year and 130.7% over two years, showing continued top-line expansion. Profitability was weak in 2025: net loss was EUR 1.9K, compared with a net profit of EUR 57.7K in 2024 and a net loss of EUR 45.8K in 2023, indicating a volatile earnings pattern. The 2025 profit margin was -0.8%, while return on assets was -0.4% and return on equity was 0.5%. As of 2025, total assets stood at EUR 527.2K, equity remained negative at EUR 390.3K, and liabilities were EUR 917.5K. The balance sheet is dominated by short-term assets, with only EUR 37 in long-term assets. Revenue per employee was EUR 80.3K, while profit per employee was negative at EUR 645, pointing to modest operational productivity but limited bottom-line conversion.